FI
VKTX icon

Financial Insights’s Viking Therapeutics VKTX Stock Holding History

Financial Insights’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,000
Closed -$243K – 158
2023
Q2 		$243K Hold
15,000
– – 0.09% 141
2023
Q1 		$250K Buy
15,000
+1,000
+7% +$10.3K 0.1% 148
2022
Q4 		$132K Sell
14,000
-14,000
-50% -$62.5K 0.06% 144
2022
Q3 		$76K Buy
+28,000
New +$91.7K 0.05% 123

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Financial Insights's VKTX Position: Q3 2023 in Review

Financial Insights sold out of Viking Therapeutics (VKTX) in Q3 2023, closing a stake of 15,000 shares — an estimated $243K sold.

Financial Insights first reported a position in VKTX in Q3 2022 and held it in 4 quarters. The position peaked at $250K in Q1 2023. 179 funds tracked by Wall St. Rank hold VKTX as of Q3 2023.

  • Financial Insights reported no remaining Viking Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Financial Insights sold 15,000 Viking Therapeutics shares in Q3 2023, an estimated $243K.
  • Financial Insights first reported a position in Viking Therapeutics in Q3 2022 and held it in 4 quarters.
  • Financial Insights's Viking Therapeutics position peaked at $250K in Q1 2023.
  • 179 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2023.

Based on Financial Insights's 13F filing for Q3 2023, filed 7 Dec 2023.